D
David McKenzie
Researcher at Celgene
Publications - 22
Citations - 4090
David McKenzie is an academic researcher from Celgene. The author has contributed to research in topics: Azacitidine & International Prognostic Scoring System. The author has an hindex of 11, co-authored 22 publications receiving 3743 citations.
Papers
More filters
Journal ArticleDOI
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study.
Pierre Fenaux,Ghulam J. Mufti,Eva Hellström-Lindberg,Valeria Santini,Carlo Finelli,Aristoteles Giagounidis,Robert Schoch,Norbert Gattermann,Guillermo Sanz,Alan F. List,Steven D. Gore,John F. Seymour,John M. Bennett,John C. Byrd,Jay Backstrom,Linda Zimmerman,David McKenzie,C.L. Beach,Lewis R. Silverman +18 more
TL;DR: Treatment with azacitidine increases overall survival in patients with higher-risk myelodysplastic syndromes relative to conventional care.
Journal ArticleDOI
Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid Leukemia
Pierre Fenaux,Ghulam J. Mufti,Eva Hellström-Lindberg,Valeria Santini,Norbert Gattermann,Ulrich Germing,Guillermo Sanz,Alan F. List,Steven D. Gore,John F. Seymour,Hervé Dombret,Jay Backstrom,Linda Zimmerman,David McKenzie,C.L. Beach,Lewis R. Silverman +15 more
TL;DR: In older adult patients with low marrow blast count (20% to 30%) WHO-defined AML, azacitidine significantly prolongs OS and significantly improves several patient morbidity measures compared with CCR.
Journal ArticleDOI
Further Analysis of Trials With Azacitidine in Patients With Myelodysplastic Syndrome: Studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B
Lewis R. Silverman,David McKenzie,Bercedis L. Peterson,James F. Holland,Jay Backstrom,C.L. Beach,Richard A. Larson +6 more
TL;DR: The combined results of three previously reported clinical trials with azacitidine using the WHO classification system for MDS and acute myeloid leukemia (AML) and IWG criteria for response provide important clinical benefits for patients with high-risk MDS.
Journal ArticleDOI
Effects of azacitidine compared with conventional care regimens in elderly (≥75 years) patients with higher-risk myelodysplastic syndromes
John F. Seymour,Pierre Fenaux,Lewis R. Silverman,Ghulam J. Mufti,Eva Hellström-Lindberg,Valeria Santini,Alan F. List,Steven D. Gore,Jay Backstrom,David McKenzie,C.L. Beach +10 more
TL;DR: AZA should be considered the treatment of choice in patients aged ≥ 75 years with good performance status and higher-risk MDS, and generally well tolerated compared with CCR, which was primarily best supportive care.
Journal ArticleDOI
Azacitidine (AZA) Treatment Prolongs Overall Survival (OS) in Higher-Risk MDS Patients Compared with Conventional Care Regimens (CCR): Results of the AZA-001 Phase III Study.
Pierre Fenaux,Ghulam J. Mufti,Valeria Santini,Carlo Finelli,A.A.N. Giagounidis,R. Schoch,A. List,Steven D. Gore,John F. Seymour,Eva Hellström-Lindberg,John M. Bennett,John C. Byrd,Jay Backstrom,Linda Zimmerman,David McKenzie,C.L. Beach,Lewis R. Silverman +16 more
TL;DR: This AZA trial is the first MDS clinical study to demonstrate a significant OS advantage, thus altering the natural disease course, and should now be considered first-line therapy for higher-risk MDS pts.